![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Allogene Therapeutics
General information
Main focus: Allogeneic CAR-T cell therapies
Company stage: Clinical
Diseases: Non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), acute myeloid leukaemia (AML), renal cell carcinoma (RCC), small cell lung cancer (SCLC)
Genome editing tool: TALEN
Funding stage: Public (NASDAQ:ALLO)
Location: San Francisco, CA, USA
Website: http://allogene.com/
Pipeline: https://www.allogene.com/pipeline
Partners: Cellectis, Servier, Notch Therapeutics, SpringWorks Therapeutics, Pfizer
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_csm_allogene_8c98a7f393_c9ddebbd83_97ba684a94_b62d74203c.jpg)
Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Allogene is developing a pipeline ofoff-the-shelf CAR-T cell therapy candidates, with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients.